Product Information Sheet for HRP-20266

Lenacapavir

Catalog No. HRP-20266

This reagent is the property of the U.S. Government.

For research use only. Not for use in humans.

Contributor:

NIH HIV Reagent Program

Manufacturer:

MedChemExpress, LLC, Monmouth Junction, New Jersey, USA

Product Description:

Lenacapavir (Sunlenca; GS-6207) is a first-in-class capsid inhibitor approved by the U.S. FDA as an antiretroviral medication to treat HIV/AIDS patients.[1,2] Lenacapavir interferes with multiple essential steps of the viral lifecycle dependent on capsids, such as nuclear transport, virus assembly and release, and capsid-core formation.[1,2] It exhibits antiviral activity at picomolar concentrations against all tested subtypes of human immunodeficiency virus type 1 (HIV-1) and shows high synergy, no cross-resistance, and minimal cytotoxicity with approved antiretroviral drugs.[1]

Material Provided:

Each vial contains approximately 2.0 mg of lenacapavir.

Note: Lenacapavir is soluble in dimethylsulfoxide (DMSO).

Packaging/Storage:

HRP-20266 was packaged in glass serum vials and is provided on ice bricks. HRP-20266 should be stored at -20°C in a cool, well-ventilated area, protected from direct sunlight and sources of ignition. For long-term storage, working aliquots of HRP-20266 can be stored at -80°C once resuspended. The vial should be centrifuged prior to opening.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH HIV Reagent Program, NIAID, NIH: Lenacapavir, HRP-20266, contributed by the NIH HIV Reagent Program."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at www.hivreagentprogram.org.

While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Link, J. O., et al. "Clinical Targeting of HIV Capsid Protein with a Long-Acting Small Molecule" Nature 584 (2020): 614-618. PubMed: 32612233.
2. Yant, S. R., et al. "A Highly Potent Long-Acting Small-Molecule HIV-1 Capsid Inhibitor with Efficacy in a Humanized Mouse Model." Nat. Med. 25 (2019): 1377-1384. PubMed: 31501601.

Support Provided by NIAID

NIH HIV Reagent Program
www.hivreagentprogram.org
E-mail: contact@HIVReagentProgram.org
Tel: **888-487-0727** | Fax: **703-365-2898**